Logo image of PROG

BIORA THERAPEUTICS INC (PROG) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PROG - US74319F1075 - Common Stock

0.8845
-0.03 (-3.47%)
Last: 5/6/2022, 8:00:02 PM
0.9
+0.02 (+1.75%)
After Hours: 5/6/2022, 8:00:02 PM
Fundamental Rating

1

Overall PROG gets a fundamental rating of 1 out of 10. We evaluated PROG against 102 industry peers in the Health Care Providers & Services industry. PROG may be in some trouble as it scores bad on both profitability and health. PROG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PROG had negative earnings in the past year.
PROG Yearly Net Income VS EBIT VS OCF VS FCFPROG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 -50M -100M -150M -200M

1.2 Ratios

Industry RankSector Rank
ROA -227.32%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PROG Yearly ROA, ROE, ROICPROG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 0 -2K -4K -6K

1.3 Margins

Industry RankSector Rank
OM -517.86%
PM (TTM) -966.06%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PROG Yearly Profit, Operating, Gross MarginsPROG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 0 -5K -10K -15K

More info and screens

1

2. Health

2.1 Basic Checks

PROG has more shares outstanding than it did 1 year ago.
PROG has a worse debt/assets ratio than last year.
PROG Yearly Shares OutstandingPROG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 50M 100M 150M
PROG Yearly Total Debt VS Total AssetsPROG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 50M 100M 150M

2.2 Solvency

PROG has an Altman-Z score of -12.84. This is a bad value and indicates that PROG is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of -1.49 indicates that PROG is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -1.49
Debt/FCF N/A
Altman-Z -12.84
ROIC/WACCN/A
WACCN/A
PROG Yearly LT Debt VS Equity VS FCFPROG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 0 100M -100M

2.3 Liquidity

A Current Ratio of 1.60 indicates that PROG should not have too much problems paying its short term obligations.
PROG has a Quick Ratio of 1.60. This is a normal value and indicates that PROG is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.6
Quick Ratio 1.6
PROG Yearly Current Assets VS Current LiabilitesPROG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

PROG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.83%, which is quite impressive.
The Revenue for PROG has decreased by -65.54% in the past year. This is quite bad
Measured over the past years, PROG shows a very negative growth in Revenue. The Revenue has been decreasing by -78.64% on average per year.
EPS 1Y (TTM)68.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.4%
Revenue 1Y (TTM)-65.54%
Revenue growth 3Y-78.64%
Revenue growth 5YN/A
Sales Q2Q%-96.95%

3.2 Future

PROG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.23% yearly.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y77.59%
EPS Next 2Y33.26%
EPS Next 3Y20.89%
EPS Next 5Y12.23%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PROG Yearly Revenue VS EstimatesPROG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 50M 100M
PROG Yearly EPS VS EstimatesPROG Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PROG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PROG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PROG Price Earnings VS Forward Price EarningsPROG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.53
PROG Per share dataPROG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PROG's earnings are expected to grow with 20.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.26%
EPS Next 3Y20.89%

More info and screens

0

5. Dividend

5.1 Amount

PROG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIORA THERAPEUTICS INC

NASDAQ:PROG (5/6/2022, 8:00:02 PM)

After market: 0.9 +0.02 (+1.75%)

0.8845

-0.03 (-3.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-10 2022-05-10/amc
Earnings (Next)08-10 2022-08-10
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners8.45%
Ins Owner Change0%
Market Cap162.92M
Revenue(TTM)25.61M
Net Income(TTM)-247.41M
Analysts82.86
Price Target4.08 (361.28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.36
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -1.53
EPS(TTM)-2.23
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.14
BVpS-0.46
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -227.32%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -517.86%
PM (TTM) -966.06%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity -1.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.6
Quick Ratio 1.6
Altman-Z -12.84
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.4%
EPS Next Y77.59%
EPS Next 2Y33.26%
EPS Next 3Y20.89%
EPS Next 5Y12.23%
Revenue 1Y (TTM)-65.54%
Revenue growth 3Y-78.64%
Revenue growth 5YN/A
Sales Q2Q%-96.95%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

BIORA THERAPEUTICS INC / PROG FAQ

What is the ChartMill fundamental rating of BIORA THERAPEUTICS INC (PROG) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PROG.


What is the valuation status for PROG stock?

ChartMill assigns a valuation rating of 0 / 10 to BIORA THERAPEUTICS INC (PROG). This can be considered as Overvalued.


How profitable is BIORA THERAPEUTICS INC (PROG) stock?

BIORA THERAPEUTICS INC (PROG) has a profitability rating of 0 / 10.


Can you provide the financial health for PROG stock?

The financial health rating of BIORA THERAPEUTICS INC (PROG) is 3 / 10.


Can you provide the expected EPS growth for PROG stock?

The Earnings per Share (EPS) of BIORA THERAPEUTICS INC (PROG) is expected to grow by 77.59% in the next year.